Otros idiomas IN8bio, Inc.

Acciones

INAB

US45674E1091

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:01 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
1 ^USD	-1,96 %		-3,85 %	-27,54 %

30/04	In8bio, Inc. Dosifica al Primer Paciente del Ensayo Clínico de Fase 2 de Inb-400 en Glioblastoma Recién Diagnosticado	CI
10/04	Principales ganancias antes de la comercialización	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma	30/04
In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma	30/04
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene and Cell Therapy 2024 Annual Meeting	25/04
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	24/04
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference	16/04
Top Premarket Gainers	10/04
North American Morning Briefing: Traders Await the CPI Report	10/04
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024	09/04
IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024	09/04
IN8bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights	14/03
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024	05/03
IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024	05/03
IN8bio to Present at Upcoming Investor Conferences	26/02
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology	14/02
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology	14/02
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals	04/01
IN8bio, Inc. announced that it has received $14.442298 million in funding from Bios Equity Partners LP	28/12
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	12/12
Top Premarket Gainers	12/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas IN8bio, Inc.

Acciones

INAB

US45674E1091

Otros idiomas

Filtros